NASDAQ:MRTX

Mirati Therapeutics News Headlines

$162.46
-0.57 (-0.35 %)
(As of 06/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$160.13
$166.51
50-Day Range
$144.00
$172.04
52-Week Range
$110.17
$249.42
Volume457,714 shs
Average Volume474,689 shs
Market Capitalization$8.36 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.42

Mirati Therapeutics (NASDAQ MRTX) News Headlines Today

SourceHeadline
Mirati Therapeutics (NASDAQ:MRTX) Upgraded by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell to BuyMirati Therapeutics (NASDAQ:MRTX) Upgraded by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell to Buy
marketbeat.com - June 4 at 7:48 AM
Mirati Therapeutics Adagrasib Gets Breakthrough Therapy DesignationMirati Therapeutics' Adagrasib Gets Breakthrough Therapy Designation
markets.businessinsider.com - June 24 at 6:09 PM
Hedge Funds Still Buying Mirati Therapeutics, Inc. (MRTX)Hedge Funds Still Buying Mirati Therapeutics, Inc. (MRTX)
finance.yahoo.com - June 17 at 12:13 PM
Citigroup Upgrades Mirati Therapeutics (NASDAQ:MRTX) to BuyCitigroup Upgrades Mirati Therapeutics (NASDAQ:MRTX) to Buy
americanbankingnews.com - June 4 at 9:26 AM
Mirati Therapeutics (NASDAQ:MRTX) Rating Increased to Buy at Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellMirati Therapeutics (NASDAQ:MRTX) Rating Increased to Buy at Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell
americanbankingnews.com - June 4 at 7:48 AM
Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate UpdatesMirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates
markets.businessinsider.com - May 6 at 7:45 PM
Were Hedge Funds Right About Piling Into Mirati Therapeutics (MRTX)?Were Hedge Funds Right About Piling Into Mirati Therapeutics (MRTX)?
finance.yahoo.com - May 4 at 12:35 PM
Is Mirati Therapeutics (MRTX) Stock A Buy or Sell?Is Mirati Therapeutics (MRTX) Stock A Buy or Sell?
finance.yahoo.com - March 23 at 1:42 PM
Mirati Therapeutics, Inc. (26M.F)Mirati Therapeutics, Inc. (26M.F)
ca.finance.yahoo.com - March 20 at 9:46 AM
7 Pharmaceutical Stocks Working on Their Next Blockbuster7 Pharmaceutical Stocks Working on Their Next Blockbuster
markets.businessinsider.com - March 12 at 4:54 PM
MRTX Mar 2021 195.000 callMRTX Mar 2021 195.000 call
au.finance.yahoo.com - March 7 at 1:33 PM
Mirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate UpdatesMirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate Updates
markets.businessinsider.com - February 25 at 5:26 PM
Why Turning Point Is Turning HeadsWhy Turning Point Is Turning Heads
msn.com - February 23 at 12:42 PM
Mirati Therapeutics To Present At Upcoming Healthcare ConferencesMirati Therapeutics To Present At Upcoming Healthcare Conferences
finance.yahoo.com - February 18 at 5:01 PM
Mirati Therapeutics To Present At Guggenheim Healthcare Talks 2021 Oncology DaysMirati Therapeutics To Present At Guggenheim Healthcare Talks 2021 Oncology Days
finance.yahoo.com - February 4 at 5:00 PM
Qorvo® to Webcast Quarterly Earnings Conference Call on February 3, 2021Qorvo® to Webcast Quarterly Earnings Conference Call on February 3, 2021
finance.yahoo.com - January 20 at 9:45 AM
MRTX Jan 2022 40.000 callMRTX Jan 2022 40.000 call
au.finance.yahoo.com - January 9 at 12:44 AM
Rogers Corp. Stock Heats Up With 83 Relative Strength RatingRogers Corp. Stock Heats Up With 83 Relative Strength Rating
finance.yahoo.com - January 7 at 6:37 PM
Dow Jones Pares Earlier Gains As Trump Rioters Storm Capitol; These Stocks Break OutDow Jones Pares Earlier Gains As Trump Rioters Storm Capitol; These Stocks Break Out
finance.yahoo.com - January 6 at 5:23 PM
Mirati Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare ConferenceMirati Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 5:36 PM
Mirati Therapeutics: Paying $220 A Share Sounds Excessive But Cracking KRAS Is A Big DealMirati Therapeutics: Paying $220 A Share Sounds Excessive But Cracking KRAS Is A Big Deal
seekingalpha.com - January 1 at 11:24 AM
Mirati Therapeutics: A Gift That Keeps On GivingMirati Therapeutics: A Gift That Keeps On Giving
seekingalpha.com - December 31 at 10:43 AM
Is MRTX A Good Stock To Buy According To Hedge Funds?Is MRTX A Good Stock To Buy According To Hedge Funds?
finance.yahoo.com - December 24 at 12:59 PM
Notable Tuesday Option Activity: MRTX, DE, SQNotable Tuesday Option Activity: MRTX, DE, SQ
nasdaq.com - December 15 at 5:30 PM
Dow Jones Futures: Tesla Rallies On S&P 500 Update; Zoom Falls On Earnings; Apple, AMD Lead Stock Market RallyDow Jones Futures: Tesla Rallies On S&P 500 Update; Zoom Falls On Earnings; Apple, AMD Lead Stock Market Rally
finance.yahoo.com - November 30 at 6:11 PM
Mirati Therapeutics To Participate In The 2020 Evercore ISI HealthCONx ConferenceMirati Therapeutics To Participate In The 2020 Evercore ISI HealthCONx Conference
finance.yahoo.com - November 23 at 8:39 PM
Dow Jones Futures: Qualcomm Near Buy Point In Tight Stock Market Rally; Apple Looks TiredDow Jones Futures: Qualcomm Near Buy Point In Tight Stock Market Rally; Apple Looks Tired
finance.yahoo.com - November 22 at 6:20 PM
Mirati Therapeutics EPS beats by $0.07Mirati Therapeutics EPS beats by $0.07
seekingalpha.com - November 4 at 6:25 PM
Mirati Therapeutics Reports Third Quarter 2020 Financial Results And Recent Business HighlightsMirati Therapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights
finance.yahoo.com - November 4 at 6:25 PM
Qualcomm Phones In Beat-And-Raise Report As 5G Kicks Into High GearQualcomm Phones In Beat-And-Raise Report As 5G Kicks Into High Gear
finance.yahoo.com - November 4 at 6:25 PM
MRTX Jan 2021 90.000 putMRTX Jan 2021 90.000 put
uk.finance.yahoo.com - November 2 at 12:53 PM
MRTX Jan 2022 75.000 putMRTX Jan 2022 75.000 put
uk.finance.yahoo.com - November 2 at 12:44 AM
MRTX Mar 2021 210.000 callMRTX Mar 2021 210.000 call
uk.finance.yahoo.com - November 1 at 7:44 PM
MRTX Dec 2020 80.000 callMRTX Dec 2020 80.000 call
uk.finance.yahoo.com - November 1 at 7:44 PM
Need To Know: The Consensus Just Cut Its Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates For 2020Need To Know: The Consensus Just Cut Its Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates For 2020
finance.yahoo.com - October 29 at 12:54 PM
Mirati Therapeutics launches equity offering of $700MMirati Therapeutics launches equity offering of $700M
seekingalpha.com - October 26 at 6:56 PM
Mirati (MRTX) Expected to Beat Earnings Estimates: Should You Buy?Mirati (MRTX) Expected to Beat Earnings Estimates: Should You Buy?
finance.yahoo.com - October 26 at 1:56 PM
Mirati Reports Promising Anti-Tumor Activity For AdagrasibMirati Reports Promising Anti-Tumor Activity For Adagrasib
finance.yahoo.com - October 26 at 8:55 AM
Barrons Picks And Pans: Coca-Cola, Sprouts Farmers Market, Mirati Therapeutics And MoreBarron's Picks And Pans: Coca-Cola, Sprouts Farmers Market, Mirati Therapeutics And More
msn.com - October 25 at 1:20 PM
Hedge Fund Darling Mirati’s $5 Billion Stock Rally Set for TestHedge Fund Darling Mirati’s $5 Billion Stock Rally Set for Test
finance.yahoo.com - October 23 at 3:08 PM
Qorvo: Stock To Watch With Earnings On DeckQorvo: Stock To Watch With Earnings On Deck
finance.yahoo.com - October 21 at 7:22 PM
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - October 21 at 2:21 PM
Qorvo® to Webcast Quarterly Earnings Conference Call on November 4, 2020Qorvo® to Webcast Quarterly Earnings Conference Call on November 4, 2020
finance.yahoo.com - October 21 at 9:20 AM
Mirati Therapeutics To Present Data During The 2020 EORTC-NCI-AACR International Virtual Conference On Molecular Targets And Therapeutics (ENA)Mirati Therapeutics To Present Data During The 2020 EORTC-NCI-AACR International Virtual Conference On Molecular Targets And Therapeutics (ENA)
markets.businessinsider.com - October 15 at 8:10 PM
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to ...INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to ...
businesswire.com - October 14 at 10:24 PM
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to ...INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to ...
businesswire.com - October 6 at 5:29 PM
Top Tech Stocks for October 2020Top Tech Stocks for October 2020
finance.yahoo.com - September 29 at 6:01 PM
Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With NivolumabMirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab
markets.businessinsider.com - September 18 at 1:14 PM
Mirati sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancerMirati' sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer
seekingalpha.com - September 18 at 1:14 PM
Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual CongressMirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual Congress
finance.yahoo.com - September 18 at 8:13 AM
Mirati Therapeutics teams up with Boehringer Ingelheim in cancer studyMirati Therapeutics teams up with Boehringer Ingelheim in cancer study
seekingalpha.com - September 17 at 12:09 PM
This page was last updated on 6/25/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.